Prevention of retinopathy of prematurity

Arquivos Brasileiros de Oftalmologia

Volumn 74, Issue 3, 2011, Pages 217-221

  Filho, João Borges Fortes ^a   Eckert, Gabriela Unchalo ^b   Tartarella, Marcia Beatriz ^c   Procianoy, Renato Soibelmann ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Blindness prevention control; Retinopathy of prematurity; Risk factors

Indexed keywords

HUMAN; NEWBORN; PROGNOSIS; RETROLENTAL FIBROPLASIA; REVIEW;

HUMANS; INFANT, NEWBORN; PROGNOSIS; RETINOPATHY OF PREMATURITY;

EID: 81355141826     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492011000300016     Document Type: Review

References (40)

1. Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, Zin A; International NOROP Group. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115(5): e518-25.
2. Wheatley CM, Dickinson JL, Mackey DA, Craig JE, Sale MM. Retinopathy of prematurity: recent advances in our understanding. Br J Ophthalmol. 2002;86(6):696-700.
3. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust. 1951;2(2):48-50.
4. Crosse VM. Retrolental fibroplasia. Ulster Med J. 1952;21(1):32-5.
5. Patz A. The role of oxygen in retrolental fibroplasia. Trans Am Ophthalmol Soc. 1968;66: 940-85.
6. Sola A, Chow L, Rogido M. [Retinopathy of prematurity and oxygen therapy: a changing relationship]. An Pediatr (Barc). 2005;62(1):48-63. Review. Spanish.
7. McGregor ML, Bremer DL, Cole C, McClead RE, Phelps DL, Fellows RR, Oden N; HOPE-ROP Multicenter Group. High Oxygen Percentage in Retinopathy of Prematurity study. Retinopathy of prematurity outcome in infants with prethreshold retinopathy of prematurity and oxygen saturation >94% in room air: the high oxygen percentage in retinopathy of prematurity study. Pediatrics. 2002;110(3):540-4.
8. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114(10):1219-28. Erratum in Arch Ophthalmol. 1997;115(3):427.
9. Tin W, Milligan DW, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed. 2001;84(2): F106-10. Comment in Arch Dis Child Fetal Neonatal Ed. 2001; 84(3):F149. Arch Dis Child Fetal Neonatal Ed. 2001;85(1): F75. Arch Dis Child Fetal Neonatal Ed. 2001;84(3): F149-50. Arch Dis Child Fetal Neonatal Ed. 2001;85(1): F75-6.
10. York JR, Landers S, Kirby RS, Arbogast PG, Penn JS. Arterial oxygen fluctuation and retinopathy of prematurity in very-low-birth-weight infants. J Perinatol. 2004;24(2):82-7.
11. Chow LC, Wright KW, Sola A; CSMC Oxygen Administration Study Group. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics. 2003;111(2):339-45.
12. Hellström A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L, et al. IGFI is critical for normal vascularization of the human retina. J Clin Endocrinol Metab. 2002; 87(7):3413-6.
13. Hellström A, Engström E, Hard AL, Bertsson-Wikland K, Carlsson B, Niklasson A, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003;112(5):1016-20.
14. Lermann VL, Fortes Filho JB, Procianoy RS. The prevalence of retinopathy of prematurity in very low birth weight newborn infants. J Pediatr (Rio J). 2006;82(1):27-32.
15. Wallace DK, Kylstra JA, Phillips SJ, Hall JG. Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAPOS. 2000;4(6):343-7.
16. Löfqvist C, Andersson E, Sigurdsson J, Engström E, Hard AL, Niklasson A, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006;124(12):1711-8. Erratum in: Arch Ophthalmol. 2007;125(3):426.
17. Fortes Filho JB, Bonomo PP, Maia M, Procianoy RS. Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):831-6.
18. Härd AL, Löfqvist C, Fortes Filho JB, Procianoy RS, Smith L, Hellström A. Predicting proliferative retinopathy in a Brazilian population of preterm infants with the screening algorithm WINROP. Arch Ophthalmol. 2010;128(11):1432-6.
19. Fortes Filho JB, Eckert GU, Valiatti FB, Dos Santos PG, da Costa MC, Procianoy RS. The influence of gestational age on the dynamic behavior of other risk factors associated with retinopathy of prematurity (ROP). Graefes Arch Clin Exp Ophthalmol. 2010;248(6): 893-900.
20. Zin A, Florêncio T, Fortes Filho JB, Nakanami CR, Gianini N, Graziano RM, Moraes N. Proposta de diretrizes brasileiras do exame e tratamento de retinopatia da prematuridade (ROP). Arq Bras Oftalmol. 2007;70(5):875-83.
21. Costa MC, Eckert GU, Valiatti FB, Bonomo PP, Fortes Filho JB. Incidência da retinopatia e a participação da enfermagem na prevenção da cegueira pela retinopatia da prematuridade no Hospital de Clínicas de Porto Alegre: estudo prospectivo observacional descritivo. Online Braz J Nurs (Online). 2007;6(3).
22. Laws DE, Morton C, Weindling M, Clark D. Systemic effects of screening for retinopathy of prematurity. Br J Ophthalmol. 1996;80(5):425-8.
23. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1988;106(4):471-9.
24. Pearce IA, Pennie FC, Gannon LM, Weindling AM, Clark DI. Three year visual outcome for treated stage 3 retinopathy of prematurity: cryotherapy versus laser. Br J Ophthalmol. 1998;82(11):1254-9.
25. Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J AAPOS. 2010;14(1):2-3. Comment on J AAPOS. 2010;14(1):6-10.
26. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008; 28(6):831-8. Erratum in Retina. 2008;28(9):1374.
27. Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38(3):233-7.
28. Reynolds JD. Bevacizumab for retinopathy of prematurity. N Engl J Med. 2011;364(7):677-8. Comment in N Engl J Med. 2011;364(24):2360-1; author reply 2362. N Engl J Med. 2011;364(24):2359; author reply 2361-2. N Engl J Med. 2011;364(7):603-15.
29. Robinson R, O'Keefe M. Follow-up study on premature infants with and without retinopathy of prematurity. Br J Ophthalmol. 1993;77(2):91-4.
30. Good WV, Hardy RJ. The multicenter study of Early Treatment for Retinopathy of Prematurity (ETROP). Ophthalmology. 2001;108(6):1013-4.
31. Holmström G, Larsson E. Long-term follow-up of visual functions in prematurely born childrena prospective population-based study up to 10 years of age. J AAPOS. 2008;12(2):157-62.
32. Graziano RM, Leone CR, Cunha SL, Pinheiro AC. Prevalência da retinopatia da prematuridade em recém-nascidos de muito baixo peso. J Pediatr (Rio J). 1997;73(6): 377-82.
33. Fortes Filho JB, Eckert GU, Valiatti FB, da Costa MC, Bonomo PP, Procianoy RS. Prevalence of retinopathy of prematurity: an institutional cross-sectional study of preterm infants in Brazil. Rev Panam Salud Publica. 2009;26(3):216-20.
34. Fortes Filho JB, Eckert GU, Procianoy L, Barros CK, Procianoy RS. Incidence and risk factors for retinopathy of prematurity in very low and in extremely low birth weight infants in a unit-based approach in southern Brazil. Eye (Lond). 2009;23(1):25-30.
35. Bonotto LB, Moreira ATR, Carvalho DS. Prevalência de retinopatia da prematuridade em prematuros atendidos no período de 1992-1999 em Joinville (SC): avaliação de riscos associados - "screening". Arq Bras Oftalmol. 2007;70(1):55-61.
36. Pinheiro AM, Silva WA, Bessa CGF, Cunha HM, Ferreira MAF, Gomes AHB. Incidência e fatores de risco da retinopatia da prematuridade no Hospital Universitário Onofre Lopes, Natal (RN) - Brasil. Arq Bras Oftalmol. 2009;72(4):451-6.
37. Schumann RF, Barbosa ADM, Valete CO. Incidência e gravidade da retinopatia da prematuridade e sua associação com morbidade e tratamentos instituídos no Hospital Universitário Antonio Pedro, entre 2003 a 2005. Arq Bras Oftalmol. 2010;73(1):47-51.
38. Shinsato RN, Paccola L, Goncalves WA, Barbosa JC, Martinez FE, Rodrigues MLV, Jorge R. Frequência de retinopatia da prematuridade em recém-nascidos no Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Arq Bras Oftalmol. 2010;73(1):60-5.
39. Quinn GE. The 'ideal' management of retinopathy of prematurity. Eye (Lond). 2005;19(10): 1044-9.
40. Zin AA, Moreira ME, Bunce C, Darlow BA, Gilbert CE. Retinopathy of prematurity in 7 neonatal units in Rio de Janeiro: screening criteria and workload implications. Pediatrics. 2010;126(2): e410-7.